JPRN-jRCTs031200073CompletedPhase 1
The efficacy of anti-IL-4/13 receptor monoclonal antibody on chronic prurigo
Tsuyoshi Namiki0 sites2 target enrollmentStarted: July 21, 2020Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 2
Study Overview
Brief Summary
In this study, two cases were successfully treated with dupilumab. Further research is needed to validate the effectiveness of dupilumab in the treatment of prurigo chronica multiformis.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 20age old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- •1) a patient with chronic prurigo
- •2) a patient who was not improved by oral anti-histamine drug and topical steroid
- •3) a patient at age 20 or over
- •4) a patient who fully understand and agree to join this clinical study
- •5) outpatient
Exclusion Criteria
- •1) a patient orally administrated immune suppressants or high-dose steroid within three months
- •2) a patient who undergo UV photo therapy
- •3) a patinet who was treated with anti-IgE antibody within four months
- •4) a patient suffering from severe visceral diseases, autoimmune diseases, blood dosorders, and mental disorders
- •5) a patient who is pregnant or breast-feed
- •6) a patinet who is infected with parasite
- •7) a patient who is sensitive to this medication
- •6) a patient judged inadequate to this study
Investigators
Similar Trials
Completed
Phase 4
Dupilumab for Prevention of Recurrence of CRSwNP After ESSChronic Rhinosinusitis With Nasal PolypsNCT04596189Centre hospitalier de l'Université de Montréal (CHUM)30
Recruiting
Phase 1
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLCNon-Small Cell Lung CancerNCT06088771Icahn School of Medicine at Mount Sinai21
Completed
Phase 4
Effects of Interleukin (IL)- 4R-alpha Inhibition on Respiratory Microbiome and Immunologic Correlates in Severe AsthmaAsthmaNCT05036733University of Michigan15
Completed
Phase 3
Dupilumab in Japanese Patients With Atopic DermatitisAtopic DermatitisNCT04678882Sanofi62
Recruiting
Early Phase 1
Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast CancerLocally Advanced Triple Negative Breast CancerTNBC - Triple-Negative Breast CancerNCT06637306Rima Patel15